Lilly (LLY) says solanezumab did not slow the progression of cognitive decline due to Alzheimer's disease in latest study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. USO
6. GOOGL
7. APGE
8. NAVN
9. DFTX
10. IBM

Go back to Lilly (LLY) says solanezumab did not slow the progression of cognitive decline due to Alzheimer's disease in latest study

Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease

March 8, 2023 5:00 PM EST

Results showed solanezumab did not slow cognitive decline in preclinical Alzheimer's disease or reduce risk of progression to symptomatic Alzheimer's disease

Solanezumab targets soluble amyloid beta, and treatment did not result in clearance of brain amyloid plaque

Lilly remains committed to fighting Alzheimer's disease, with plaque-clearing mechanisms such as donanemab and remternetug, both in ongoing Phase 3 trials

INDIANAPOLIS, March 8, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:... More